Therapy Areas: Inflammatory Diseases
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
29 October 2025 - Animal health business Zoetis Inc (NYSE: ZTS) announced on Wednesday that the European Commission has granted marketing authorization for Portela (relfovetmab), the first monoclonal ...
Johnson & Johnson reports durable two-year remission data for TREMFYA in Crohn's disease
27 October 2025 - US healthcare company Johnson & Johnson (NYSE: JNJ) on Monday announced new 96-week data from the Phase 3 GRAVITI, GALAXI 2, and GALAXI 3 studies, confirming the long-term effica...
Trellus Health signs contract with leading global CRO and expands clinical trial offerings
22 October 2025 - Healthcare company Trellus Health plc (AIM: TRLS) announced on Wednesday that it has signed a 12-month contract with one of the world's largest Clinical Research Organisations (...
Genentech's Gazyva (obinutuzumab) receives US FDA approval to treat adults with lupus nephritis
21 October 2025 - The Lupus Foundation of America Inc reported on Monday that the US Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab), developed by biotechnology company Genentech...
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
20 October 2025 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Monday that it has received US Food and Drug Administration (FDA) approval for Tezspire (te...
CStone announces Phase I CS2009 data at ESMO 2025
20 October 2025 - CStone Pharmaceuticals (HKEX:2616), a China-based biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key ...